Oxford Immunotec Limited (OXFD) Schedules Fourth Quarter And Full Year 2013 Earnings Release And Conference Call For March 4, 2014
2/24/2014 2:08:36 PM
OXFORD, UK and MARLBOROUGH, MA, Feb. 24, 2014 (GLOBE NEWSWIRE) – Oxford Immunotec
Global PLC (Nasdaq: OXFD) today announced that it plans to release fourth quarter and full year 2013
financial results prior to market open on Tuesday, March 4, 2014. Dr. Peter Wrighton-Smith, Chief
Executive Officer and Rick Altieri, Chief Financial Officer will host a conference call to review the
Company’s results at 8:00am Eastern Time the same day. The call will be concurrently webcast.
To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers
and +1 (484) 365-2897 for international callers and reference confirmation code 2444858, approximately
ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit
the Investor Relations section of Oxford Immunotec’s website at http://www.oxfordimmunotec.com. The
replay will be available on the Company’s website for approximately 90 days.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company committed to
improving patient care by providing advanced, innovative tests in the field of immunology. The proprietary
T-SPOT® technology platform measures the responses of specific immune cells, known as T cells, to
inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases. T
cells are a central component of the human body’s immune system, and are implicated in the control and
progression of many medical conditions, including certain types of infectious diseases, cancers and
autoimmune diseases. The Company’s initial product developed using the T-SPOT technology platform is
the T-SPOT.TB test, which is used to test for latent tuberculosis infection. The T-SPOT.TB test has been
approved for sale in over 50 countries, including the United States, where it has received pre-market
approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as
Japan and China. The Company is headquartered near Oxford, UK and in Marlborough, MA. Additional
information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
For Media Inquiries:
Tel: +44 1235 442796
For Investor Inquiries:
Chief Financial Officer,
Tel: +1 (508) 481-4648
Tel: +1 (443) 213-0500
SOURCE: Oxford Immunotec
Help employers find you! Check out all the jobs and post your resume.
comments powered by